Flowers, Christopher R.; Veenstra, David - In: PharmacoEconomics 22 (2004) 8, pp. 481-493
The broad availability of genetic information and technologies heralds an era when practitioners will utilise genomic testing to individualise patients Assessing the incremental cost effectiveness of a pharmacogenomic strategy involves examination of factors associated with the genotype of...